Finding ways to disrupt recycling processes in pancreatic cancer cells
Identifying and disabling new pathways for macromolecular recycling in pancreatic cancer
This study is looking at a tough type of cancer called pancreatic ductal adenocarcinoma (PDAC) to find out how certain proteins help cancer cells survive, with the goal of creating new treatments that could slow down or stop the cancer from growing.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11129546 on NIH RePORTER |
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a challenging cancer with a very short survival rate. The study aims to identify specific proteins in lysosomes that help PDAC cells survive in harsh conditions. By understanding these proteins, researchers hope to develop targeted therapies that can inhibit their function, potentially slowing down or stopping tumor growth. The approach includes advanced proteomic analysis to map out these proteins in both cancerous and non-cancerous cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma.
Not a fit: Patients with other types of cancer or those without pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve survival rates for patients with pancreatic cancer.
How similar studies have performed: Previous studies have shown promising results with lysosomal inhibition therapies in prolonging survival in pancreatic cancer patients, indicating a potential for success in this approach.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Perera, Rushika Miriam — University of California, San Francisco
- Study coordinator: Perera, Rushika Miriam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.